Asset

Amphetamine sulfate

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Revenue

No revenue reported in loaded filings.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00150579phase3completed2005-01-272005-06-14ShireEfficacy and Safety of SPD465 in Adults With ADHD
NCT00202605phase2completed2005-09-292006-01-06ShireSafety and Efficacy of SPD465 in Adults With ADHD
NCT00152035phase3completed2005-03-102006-11-07ShireSafety of SPD465 in Treating Adults With ADHD.

FDA applications (2)

ApplicationTypeApplicant
NDA 021303NDATAKEDA PHARMACEUTICALS USA INC
NDA 022063NDATAKEDA PHARMACEUTICALS USA INC

Marketed products (10)

  • ADDERALL XR 10
  • ADDERALL XR 15
  • ADDERALL XR 20
  • ADDERALL XR 25
  • ADDERALL XR 30
  • ADDERALL XR 5
  • MYDAYIS
  • MYDAYIS
  • MYDAYIS
  • MYDAYIS